Table 5.
Comparing the efficacy of omadacycline with those of other drugs in the HFS-MAC
| Drug | E max (log10 cfu/mL) | Kill below stasis (log10 cfu/mL) at maximal effect | Comment |
|---|---|---|---|
| Azithromycin27 | 2.11 | 0.60 | High dose required to achieve Emax.53 |
| Ethambutol54 | 0.79 | – | Bacterial burden does not decrease below day 0 value. |
| Moxifloxacin55 | 3.03 | 3.00 | MICs for clinical isolates too high to be useful.55 |
| Linezolid10 | 2.10 | 1.06 | Poorly tolerated by patients. |
| Tedizolid9 | 3.78 | 2.07 | Tolerability in long therapy duration unknown. |
| Ceftazidime/avibactam7 | 2.71 | 2.44 | Short half-life; requires frequent dosing per day. |
| Rifabutin49 | 4.29 | 3.59 | Potential combination; good intracellular penetration. |
| Rifampicin49 | 2.69 | 2.68 | Potential combination; poor intralesional penetration. |
| Rifapentine49 | 3.14 | 3.03 | Potential combination. |
| Minocycline11 | 7.29 | 3.60 | Microbial ribosomal protection proteins and efflux pumps. |
| Omadacycline [current] | 8.41 | 4.86 | Referent. |